GlaxoSmithKline Pharmaceuticals Limited GLAXO.NS Open GlaxoSmithKline Pharmaceuticals Limited in new tab
GlaxoSmithKline Pharmaceuticals Limited Analysis (GLAXO.NS)
Is GlaxoSmithKline Pharmaceuticals Limited a good investment? GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) is currently trading at 2389.80 INR. Market analysts have a consensus price target of 2969.75 INR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 40.65. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: GlaxoSmithKline Pharmaceuticals Limited is expected to release its next earnings report on July 31, 2026. The market consensus estimate for Forward EPS is 77.28.
For income investors, GlaxoSmithKline Pharmaceuticals Limited pays a dividend yield of 2.30%. With a payout ratio of 70%, the dividend appears sustainable.
Investor FAQ
Does GlaxoSmithKline Pharmaceuticals Limited pay a dividend?
Yes, it pays an annual dividend of 54.00 INR (2.30% yield).
What asset class is GlaxoSmithKline Pharmaceuticals Limited?
GlaxoSmithKline Pharmaceuticals Limited is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be July 31, 2026. The company currently has a trailing EPS of 59.99.
Company Profile
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostrix for immunization against diphtheria, tetanus and pertussis; Fluarix Tetra for the prevention of influenza disease; Varilrix for active immunization against varicella; and Shingrix for prevention of herpes zoster and post-herpetic neuralgia. It also provides specialty medicines, such as NUCALA for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome; and Trelegy Ellipta for treating chronic obstructive pulmonary disease. In addition, the company offers general medicines, including AUGMENTIN and CEFTUM, an oral antibiotic to treat bacterial infections; CobadexCZS to treat mineral and vitamins deficiency states; Flutivate, a skin cream for adults, children, and infants; Tenovate to treat inflammatory and pruritic manifestations of steroid responsive dermatosis; CALPOL to treat mild to moderate pain; ELTROXIN for hypothyroidism; CCM to treat calcium and vitamin D deficiency; NEOSPORIN for treatment of specific bacterial skin infections; BETNOVATE for skin conditions; T-BACT for bacterial skin infections; and PHYSIOGEL for dry skin associated with redness and itch. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. The company was incorporated in 1924 and is based in Mumbai, India. GlaxoSmithKline Pharmaceuticals Limited operates as a subsidiary of GSK plc.
Dividend Yield
2.30% (5y avg: 1.73%)
Annual Dividends
54.00 INR
Next ex. div date
May 29, 2026
Payout Ratio
69.93%
Historical Dividends
| Year | Total Dividends |
|---|---|
| 2026 | 57.00 INR |
| July 1, 2026 | 57.0000 |
| 2025 | 42.00 INR |
| June 30, 2025 | 42.0000 |
| 2024 | 44.00 INR |
| Nov. 12, 2024 | 12.0000 |
| July 28, 2024 | 32.0000 |
| 2023 | 32.00 INR |
| Aug. 25, 2023 | 32.0000 |
| 2022 | 90.00 INR |
| Aug. 25, 2022 | 90.0000 |
| 2021 | 30.00 INR |
| Aug. 26, 2021 | 30.0000 |
| 2020 | 40.00 INR |
| Aug. 26, 2020 | 40.0000 |
| 2019 | 20.00 INR |
| Aug. 21, 2019 | 20.0000 |
| 2018 | 35.00 INR |
| Aug. 23, 2018 | 35.0000 |
| 2017 | 30.00 INR |
| Aug. 24, 2017 | 30.0000 |
| 2016 | 50.00 INR |
| Aug. 27, 2016 | 50.0000 |
| 2015 | 62.50 INR |
| Aug. 30, 2015 | 62.5000 |
| 2014 | 50.00 INR |
| May 17, 2014 | 50.0000 |
| 2013 | 50.00 INR |
| April 17, 2013 | 50.0000 |
| 2012 | 45.00 INR |
| April 11, 2012 | 45.0000 |
| 2011 | 40.00 INR |
| March 30, 2011 | 40.0000 |
| 2010 | 30.00 INR |
| April 24, 2010 | 30.0000 |
| 2009 | 40.00 INR |
| April 2, 2009 | 40.0000 |
| 2008 | 36.00 INR |
| April 21, 2008 | 36.0000 |
| 2007 | 31.00 INR |
| March 30, 2007 | 31.0000 |
| 2006 | 28.00 INR |
| April 12, 2006 | 28.0000 |
| 2005 | 24.00 INR |
| March 30, 2005 | 24.0000 |
| 2004 | 10.00 INR |
| March 13, 2004 | 10.0000 |
| 2003 | 7.00 INR |
| May 2, 2003 | 7.0000 |
Yearly aggregated dividends
Dividends
|
GlaxoSmithKline Pharmaceuticals Limited
Jul 01, 2026 Upcoming
Dividend
57.0 INR |
|
GlaxoSmithKline Pharmaceuticals Limited
Jun 30, 2025 Paid
Dividend
42.0 INR |
Historical Split Corporate Actions
| Split Date | Split Ratio to 1 |
|---|---|
| Sept. 11, 2018 | 2.000000 |
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion